Retatrutide · 39 amino acids

Retatrutide vs Ozempic: Head-to-Head Trial Results


Retatrutide beat Ozempic in its first head-to-head phase 3 trial. On Oct 28, 2026, Eli Lilly reported topline results from TRANSCEND-T2D-2: in 1,298 adults with type 2 diabetes, retatrutide lowered A1C by 2.2 points vs 1.8 points on semaglutide 2 mg (Ozempic), and cut body weight by up to 20.9% vs 9.4% over 80 weeks. That is roughly double the weight loss. The catch: these are company-reported numbers, not yet peer reviewed, and retatrutide is still not approved.

Key facts

What the trial actually tested

This was the first phase 3 trial to put retatrutide against another incretin drug (the hormone-based class that includes Ozempic and Mounjaro), according to AJMC. People were randomized 2:2:1 to retatrutide 9 mg, retatrutide 12 mg, or semaglutide 2 mg, all once weekly. On average, participants started at 225.8 lb with a BMI of 36.8 and an A1C of 8.3%.

The main goal was modest on purpose: show that retatrutide 12 mg was at least as good as Ozempic on A1C (a “noninferiority” test). It cleared that bar and then went further, proving superior on A1C (P < .001). The 9 mg dose also met noninferiority, and its edge over Ozempic reached nominal significance, meaning it looked better but sat outside the trial’s formal statistical safety net for multiple comparisons.

The weight loss, in plain numbers

Retatrutide 9 mg Retatrutide 12 mg Ozempic 2 mg
A1C change -2.2 points -2.2 points -1.8 points
Weight change -19.5% (44.3 lb) -20.9% (47.4 lb) -9.4% (20.9 lb)
Stopped due to side effects 4.8% 7.9% 2.7%

Why this matters: people with type 2 diabetes usually lose less weight on these drugs than people without diabetes. Robert Dubin, MD, of Pennington Biomedical, told Healio that more than 20% weight loss is the most compelling finding in a group where big weight loss has been hard to reach. Lilly also reported bigger improvements in non-HDL cholesterol, triglycerides and systolic blood pressure, but did not share the size of those differences.

Side effects, honestly

The pattern looks like the rest of the class: mostly stomach and gut effects, mostly mild to moderate, and usually easing during treatment, per AJMC.

The number to watch is discontinuation. More people quit retatrutide 12 mg because of side effects (7.9%) than quit Ozempic (2.7%). Dubin also flagged urinary tract infections as worth follow-up in the full data.

The fine print

Three things keep this from being the final word:

  1. Open-label. Everyone knew which drug they were on, which can shape how side effects get reported.
  2. Efficacy estimand. The headline numbers assume people stayed on treatment for the full 80 weeks without adding other diabetes drugs. Real-world results, which count dropouts, usually come in lower.
  3. Topline only. This is a press-release readout. Peer review, long-term safety and heart outcome data will decide where retatrutide fits.

The next big test is TRIUMPH-5, an ongoing head-to-head trial of retatrutide vs tirzepatide (Zepbound, Mounjaro) in adults with obesity, with or without type 2 diabetes.

What it means for you

If you have type 2 diabetes, this is encouraging news about where treatment is heading, not something you can get today. Retatrutide is not approved and is not sold by any legitimate pharmacy; anything marketed online as “retatrutide” is an unapproved product. The medicines a licensed provider can prescribe now are approved options like semaglutide and tirzepatide, and our semaglutide vs tirzepatide comparison walks through that choice.

For where retatrutide stands with the FDA, see when retatrutide may be available and the legal status tracker. For the bigger picture, read what retatrutide is and our three-way comparison. The right next step is a conversation with a licensed provider about your A1C, weight goals and the options that exist today.

Sources

← All articles